{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:59:00Z","timestamp":1763755140615,"version":"3.45.0"},"reference-count":50,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology Nursing Forum"],"published-print":{"date-parts":[[2007,1,1]]},"DOI":"10.1188\/07.onf.693-701","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T10:52:01Z","timestamp":1187866321000},"page":"693-701","source":"Crossref","is-referenced-by-count":2,"title":["Nursing Considerations of Bevacizumab Use in Multiple Tumor Types"],"prefix":"10.1188","volume":"34","author":[{"given":"Barbara Holmes","family":"Gobel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,6,15]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Bendell, J.C., Fernando, N., Morse, M., Blobe, G., Yu, D., Sutton, L., et al. (2006). A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer [Abstract 3541]. <i>Journal of Clinical Oncology<\/i>, 24(Suppl. 18, Pt. I), 156S.","DOI":"10.1200\/jco.2006.24.18_suppl.3541"},{"key":"E00002","doi-asserted-by":"crossref","unstructured":"Bergsland, E., & Dickler, M.N. (2004). Maximizing the potential of bevacizumab in cancer treatment. <i>Oncologist<\/i>, 9(Suppl. 1), 36-42.","DOI":"10.1634\/theoncologist.9-suppl_1-36"},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Berry, S., Cunningham, D., Michael, M., Di Bartolomeo, M., Rivera, F., Kretzschmar, F., et al. (2006b). Preliminary safety of bevacizumab with first-line FOLFOX, CAPOX, FOLFIRI, and capecitabine for mcolorectal cancer\u2014first BEATrial [Abstract 3534]. <i>Journal of Clinical Oncology<\/i>, 24(Suppl. 18, Pt. I), 154S.","DOI":"10.1200\/jco.2006.24.18_suppl.3534"},{"key":"E00004","unstructured":"Berry, S., Michael, M., Kretzschmar, A., Cunningham, D., DiBartolomeo, M., Rivera, B., et al. (2006a). Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing\/bleeding complications: Preliminary results from first BEAT [Abstract 245]. <i>Proceedings of the 2006 Gastrointestinal Cancers Symposium.<\/i>"},{"key":"E00005","unstructured":"Carroll, M.F., & Temte, J.L. (2000). Proteinuria in adults: A diagnostic approach. <i>American Family Physician<\/i>, 62, 1333-1340."},{"key":"E00006","doi-asserted-by":"crossref","unstructured":"Fernando, N.H., & Hurwitz, H.I. (2004). Targeted therapy of colorectal cancer: Clinical experience with bevacizumab. <i>Oncologist<\/i>, 9(Suppl. 1), 11-18.","DOI":"10.1634\/theoncologist.9-suppl_1-11"},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Ferrara, N. (2004). Vascular endothelial growth factor as a target for anticancer therapy. <i>Oncologist<\/i>, 9(Suppl. 1), 2-10.","DOI":"10.1634\/theoncologist.9-suppl_1-2"},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Ferrara, N., & Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. <i>Endocrine Reviews<\/i>, 18, 4-25.","DOI":"10.1210\/edrv.18.1.0287"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Ferrara, N., & Kerbel, R.S. (2005). Angiogenesis as a therapeutic target. <i>Nature<\/i>, 438, 967-974.","DOI":"10.1038\/nature04483"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Franson, P.J., & Lapka, D.V. (2005). Antivascular endothelial growth factor monoclonal antibody therapy: A promising paradigm in colorectal cancer. <i>Clinical Journal of Oncology Nursing<\/i>, 9, 55-60.","DOI":"10.1188\/05.CJON.55-60"},{"key":"E00011","unstructured":"Genentech, Inc. (2005). Avastin\u00ae (bevacizumab) for intravenous use [Package insert]. South San Francisco, CA: Author."},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Gerber, H.P., & Ferrara, N. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. <i>Cancer Research<\/i>, 65, 671-680.","DOI":"10.1158\/0008-5472.671.65.3"},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Giantonio, B., Catalano, G., Meropol, N.J., O'Dwyer, P.J., Mitchell, E.P., Alberts, S.R., et al. (2005). High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [Abstract 2]. <i>Journal of Clinical Oncology<\/i>, 23(Suppl. 16, Pt. I), 1S.","DOI":"10.1200\/jco.2005.23.16_suppl.2"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Gobel, B.H. (2005). Chemotherapy-induced hypersensitivity reactions. <i>Oncology Nursing Forum<\/i>, 32, 1027-1035.","DOI":"10.1188\/05.ONF.1027-1035"},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Goldberg, R.M., Sargent, D.J., Morton, R.F., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K., et al. (2004). A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. <i>Journal of Clinical Oncology<\/i>, 22, 23-30.","DOI":"10.1200\/JCO.2004.09.046"},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Hambleton, J., Skillings, J., Kabbinavar, F., Bergsland, E., Holmgren, E., Holden, S.N., et al. (2005). Safety of low-dose aspirin (ASA) in a pooled analysis of three randomized, controlled (RCTs) trials of bevacizumab (BV) with chemotherapy (CT) in patients with metastatic colorectal cancer (mcolorectal cancer) [Abstract 3554]. <i>Journal of Clinical Oncology<\/i>, 23(Suppl. 16, Pt. I), 259S.","DOI":"10.1200\/jco.2005.23.16_suppl.3554"},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Hedrick, E., Kozloff, M., Hainsworth, J., Badarinath, A., Cohn, A., Flynn, P., et al. (2006). Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the United States (BRiTE) [Abstract 3536]. <i>Journal of Clinical Oncology<\/i>, 24(Suppl. 18, Pt. I), 155S.","DOI":"10.1200\/jco.2006.24.18_suppl.3536"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Hochster, H.S., Hart, L., Ramanathan, R.K., Hainsworth, J.D., Griffing, S., Mass, R.D., et al. (2006). Safety and efficacy of oxaliplatin\/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mcolorectal cancer): Final analysis of the TREE-Study [Abstract 3510]. <i>Journal of Clinical Oncology<\/i>, 24(Suppl. 18, Pt. I), 148S.","DOI":"10.1200\/jco.2006.24.18_suppl.3510"},{"key":"E00019","doi-asserted-by":"crossref","unstructured":"Holden, S., Ryan, E., Kearns, A., Holmgren, E., & Hurwitz, H. (2005). Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mcolorectal cancer) [Abstract 3555]. <i>Journal of Clinical Oncology<\/i>, 23(Suppl. 16, Pt. I), 259s.","DOI":"10.1200\/jco.2005.23.16_suppl.3555"},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T., & Jaffe, R.B. (2002). Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. <i>American Journal of Pathology<\/i>, 161, 1917-1924.","DOI":"10.1016\/S0002-9440(10)64467-7"},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. <i>New England Journal of Medicine<\/i>, 350, 2335-2342.","DOI":"10.1056\/NEJMoa032691"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Hurwitz, H.I., Fehrenbacher, L., Hainsworth, J.D., Heim, W., Berlin, J., Holmgren, E., et al. (2005). Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. <i>Journal of Clinical Oncology<\/i>, 23, 3502-3508.","DOI":"10.1200\/JCO.2005.10.017"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Jain, R.K. (2005). Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. <i>Science<\/i>, 307, 58-62.","DOI":"10.1126\/science.1104819"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M., et al. (2004). Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. <i>Journal of Clinical Oncology<\/i>, 22, 2184-2191.","DOI":"10.1200\/JCO.2004.11.022"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., et al. (2003). Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology<\/i>, 21, 60-65.","DOI":"10.1200\/JCO.2003.10.066"},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Kabbinavar, F.F., Schulz, J., McCleod, M., Patel, T., Hamm, J.T., Hecht, J.R., et al. (2005). Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. <i>Journal of Clinical Oncology<\/i>, 23, 3697-3705.","DOI":"10.1200\/JCO.2005.05.112"},{"key":"E00027","doi-asserted-by":"crossref","unstructured":"Kopetz, S., Abbruzzese, J.L., Eng, C., Adinin, R.B., Morris, J., Wolff, R.A., et al. (2006). Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mcolorectal cancer) [Abstract 3579]. <i>Journal of Clinical Oncology<\/i>, 24(Suppl. 18, Pt. I), 165S.","DOI":"10.1200\/jco.2006.24.18_suppl.3579"},{"key":"E00028","doi-asserted-by":"crossref","unstructured":"Kozloff, M., Hainsworth, J., Badarinath, S., Cohn, A., Flynn, P., Steis, R., et al. (2006). Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE) [Abstract 3537]. <i>Journal of Clinical Oncology<\/i>, 24(Suppl. 18, Pt. 1), 155s.","DOI":"10.1200\/jco.2006.24.18_suppl.3537"},{"key":"E00029","unstructured":"Kretzschmar, A., Cunningham, D., Berry, S., DiBartolomeo, M., Michael, M., Rivera, F., et al. (2006). Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line (mcolorectal cancer) without primary tumor resection: Preliminary results from the first BEATrial [Abstract 248]. <i>Proceedings of the 2006 Gastrointestinal Cancers Symposium.<\/i>"},{"key":"E00030","doi-asserted-by":"crossref","unstructured":"Mass, R., Sarkar, S., Holden, S., & Hurwitz, H. (2005). Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients with metastatic colorectal cancer (mcolorectal cancer) [Abstract 3514]. <i>Journal of Clinical Oncology<\/i>, 23(Suppl. 16, Pt. 1), 249S.","DOI":"10.1200\/jco.2005.23.16_suppl.3514"},{"key":"E00031","doi-asserted-by":"crossref","unstructured":"Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcom, P.K., Fehrenbacher, L., et al. (2005a). Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. <i>Journal of Clinical Oncology<\/i>, 23, 792-799.","DOI":"10.1200\/JCO.2005.05.098"},{"key":"E00032","unstructured":"Miller, K.D., Wang, M., Gralow, J., Dickler, M., Cobleigh, M.A., Perez, E.A., et al. (2005b). A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). <i>Breast Cancer Research and Treatment<\/i>, 94(Suppl. 1), S6."},{"key":"E00033","doi-asserted-by":"crossref","unstructured":"Novotny, W.F., Holmgren, E., Nelson, B., Mass, R., Kabbinavar, F., & Hurwitz, H. (2004). Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer [Abstract 3529]. <i>Journal of Clinical Oncology<\/i>, 22(Suppl. 14), 252.","DOI":"10.1200\/jco.2004.22.14_suppl.3529"},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Ralston, S.H., Caine, N., Richards, I., O'Reilly, D., Sturrock, R.D., & Capell, H.A. (1988). Screening for proteinuria in a rheumatology clinic: Comparison of dipstick testing, 24 hour urine quantitative protein, and protein\/creatinine ratio in random urine samples. <i>Annals of the Rheumatic Diseases<\/i>, 47, 759-763.","DOI":"10.1136\/ard.47.9.759"},{"key":"E00035","unstructured":"Reiger, P. (2001). Patient management: Assessment during therapy. In P. Reiger (Ed.), <i>Biotherapy: A comprehensive overview.<\/i> (2nd ed., p. 465). Sudbury, MA: Jones and Bartlett."},{"key":"E00036","doi-asserted-by":"crossref","unstructured":"Rodby, R.A., Rohde, R.D., Sharon, Z., Pohl, M.A., Bain, R.P., Lewis, E.J., et al. (1995). The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. <i>American Journal of Kidney Diseases<\/i>, 26, 904-909.","DOI":"10.1016\/0272-6386(95)90054-3"},{"key":"E00037","doi-asserted-by":"crossref","unstructured":"Rosiak, J., & Sadowski, L. (2005). Hypertension associated with bevacizumab. <i>Clinical Journal of Oncology Nursing<\/i>, 9, 407-411.","DOI":"10.1188\/05.CJON.407-411"},{"key":"E00038","doi-asserted-by":"crossref","unstructured":"Saltz, L.B., Chung, K.Y., Timoney, J., Park, V., & Hollywood, E. (2006). Simplification of bevacizumab (bev) administration: Do we need 90, 60, or even 30 minute infusion times? [Abstract 3542]. <i>Journal of Clinical Oncology<\/i>, 24(Suppl. 18, Pt. I), 256S.","DOI":"10.1200\/jco.2006.24.18_suppl.3542"},{"key":"E00039","doi-asserted-by":"crossref","unstructured":"Saltz, L.B., Lenz, H.J., Hochster, H., Wadler, S., Hoff, P., Kemeny, N., et al. (2005). Randomized phase II trial of cetuximab\/bevacizumab\/irinotecan (CBI) versus cetuximab\/bevacizumab (CB) in irinotecan-refractory colorectal cancer [Abstract 3508]. <i>Journal of Clinical Oncology<\/i>, 23(Suppl. 16, Pt. I), 248S.","DOI":"10.1200\/jco.2005.23.16_suppl.3508"},{"key":"E00040","doi-asserted-by":"crossref","unstructured":"Sandler, A., Gray, R., Brahmer, J., Dowlati, A., Schiller, J.H., Perry, M.C., et al. (2005). Randomized phase II\/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [Abstract 4]. <i>Journal of Clinical Oncology<\/i>, 23(Suppl. 16, Pt. I), 2S.","DOI":"10.1200\/jco.2005.23.16_suppl.lba4"},{"key":"E00041","doi-asserted-by":"crossref","unstructured":"Saudan, P.J., Brown, M.A., Farrell, T., & Shaw, L. (1997). Improved methods of assessing proteinuria in hypertensive pregnancy. <i>British Journal of Obstetrics and Gynaecology<\/i>, 104, 1159-1164.","DOI":"10.1111\/j.1471-0528.1997.tb10940.x"},{"key":"E00042","doi-asserted-by":"crossref","unstructured":"Scappaticci, F.A., Fehrenbacher, L., Cartwright, T., Hainsworth, J.D., Heim, W., Berlin, J., et al. (2005). Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. <i>Journal of Surgical Oncology<\/i>, 91, 173-180.","DOI":"10.1002\/jso.20301"},{"key":"E00043","doi-asserted-by":"crossref","unstructured":"Skillings, J., Johnson, D., Miller, K., Kabbinavar, F., Bergsland, E., Holmgren, E., et al. (2005). Arterial thromboembolic events (ATEs) in a pooled analysis of five randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy [Abstract 3019]. <i>Journal of Clinical Oncology<\/i>, 23(Suppl. 16, Pt. I), 16S.","DOI":"10.1200\/jco.2005.23.16_suppl.3019"},{"key":"E00044","doi-asserted-by":"crossref","unstructured":"Sugrue, M., Kozloff, M., Hainsworth, J., Badarinath, S., Cohn, A., Flynn, P., et al. (2006). Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy [Abstract 3535]. <i>Journal of Clinical Oncology<\/i>, 24(Suppl. 18, Pt. I), 154S.","DOI":"10.1200\/jco.2006.24.18_suppl.3535"},{"key":"E00045","unstructured":"Sweeney, C.J., Miller, K.D., Sissons, S.E., Nozaki, S., Heilman, D.K., Shen, J., et al. (2001). The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. <i>Cancer Research<\/i>, 61, 3369-3372."},{"key":"E00046","doi-asserted-by":"crossref","unstructured":"Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., et al. (2003). Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. <i>British Journal of Cancer<\/i>, 88, 1979-1986.","DOI":"10.1038\/sj.bjc.6601005"},{"key":"E00047","doi-asserted-by":"crossref","unstructured":"Wilkes, G.M. (2005). Therapeutic options in the management of colon cancer: 2005 update. <i>Clinical Journal of Oncology Nursing<\/i>, 9, 31-44.","DOI":"10.1188\/05.CJON.31-44"},{"key":"E00048","doi-asserted-by":"crossref","unstructured":"Willett, C.G., Boucher, Y., di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. <i>Nature Medicine<\/i>, 10, 145-147.","DOI":"10.1038\/nm988"},{"key":"E00049","doi-asserted-by":"crossref","unstructured":"Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., et al. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. <i>New England Journal of Medicine<\/i>, 349, 427-434.","DOI":"10.1056\/NEJMoa021491"},{"key":"E00050","doi-asserted-by":"crossref","unstructured":"Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R.K. (1996). Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody. <i>Proceedings of the National Academy of Sciences of the United States of America<\/i>, 93, 14765-14770.","DOI":"10.1073\/pnas.93.25.14765"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/B08W88T78563J583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:20Z","timestamp":1763754680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/34\/3\/nursing-considerations-bevacizumab-use-multiple-tumor-types"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,1,1]]}},"alternative-id":["B08W88T78563J583"],"URL":"https:\/\/doi.org\/10.1188\/07.onf.693-701","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"type":"print","value":"0190-535X"},{"type":"electronic","value":"1538-0688"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}